Pirfenidone treatment of idiopathic pulmonary fibrosis (Q56905292)

From Wikidata

Jump to navigation Jump to search

No description defined

edit

Language	Label	Description	Also known as
English	Pirfenidone treatment of idiopathic pulmonary fibrosis	No description defined

Statements

instance of

scholarly article

0 references

title

Pirfenidone treatment of idiopathic pulmonary fibrosis (English)

0 references

main subject

pulmonary fibrosis

1 reference

based on heuristic

inferred from title

idiopathic pulmonary fibrosis

1 reference

based on heuristic

inferred from title

author name string

Arata Azuma

series ordinal

1

0 references

publication date

14 February 2012

0 references

published in

Therapeutic advances in respiratory disease

0 references

volume

6

0 references

issue

2

0 references

page(s)

107-114

0 references

cites work

Pirfenidone: antifibrotic agent for idiopathic pulmonary fibrosis

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1177%2F1753465812436663

retrieved

21 January 2018

Double-blind, placebo-controlled trial of pirfenidone in patients with idiopathic pulmonary fibrosis

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1177%2F1753465812436663

retrieved

21 January 2018

Exploratory analysis of a phase III trial of pirfenidone identifies a subpopulation of patients with idiopathic pulmonary fibrosis as benefiting from treatment

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1177%2F1753465812436663

retrieved

21 January 2018

Combined pulmonary fibrosis and emphysema: a distinct underrecognised entity.

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1177%2F1753465812436663

retrieved

21 January 2018

Ascertainment of individual risk of mortality for patients with idiopathic pulmonary fibrosis

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1177%2F1753465812436663

retrieved

21 January 2018

Effect of pirfenidone on the pulmonary fibrosis of Hermansky-Pudlak syndrome

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1177%2F1753465812436663

retrieved

21 January 2018

Effect of interferon gamma-1b on survival in patients with idiopathic pulmonary fibrosis (INSPIRE): a multicentre, randomised, placebo-controlled trial

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1177%2F1753465812436663

retrieved

21 January 2018

Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1177%2F1753465812436663

retrieved

21 January 2018

Pirfenidone suppresses tumor necrosis factor-alpha, enhances interleukin-10 and protects mice from endotoxic shock

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1177%2F1753465812436663

retrieved

21 January 2018

Antifibrotic action of pirfenidone and prednisolone: different effects on pulmonary cytokines and growth factors in bleomycin-induced murine pulmonary fibrosis

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1177%2F1753465812436663

retrieved

21 January 2018

An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1177%2F1753465812436663

retrieved

21 January 2018

Pirfenidone in idiopathic pulmonary fibrosis: the CAPACITY program

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1177%2F1753465812436663

retrieved

21 January 2018

Antifibrotic activities of pirfenidone in animal models

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1177%2F1753465812436663

retrieved

21 January 2018

Pirfenidone in idiopathic pulmonary fibrosis

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1177%2F1753465812436663

retrieved

21 January 2018

The clinical significance of 5% change in vital capacity in patients with idiopathic pulmonary fibrosis: extended analysis of the pirfenidone trial

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1177%2F1753465812436663

retrieved

21 January 2018

Marginal decline in forced vital capacity is associated with a poor outcome in idiopathic pulmonary fibrosis

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1177%2F1753465812436663

retrieved

21 January 2018

Identifiers

DOI

10.1177/1753465812436663

0 references

PubMed publication ID

22333982

0 references

 

Sitelinks

Wikipedia(0 entries)

edit

Wikibooks(0 entries)

edit

Wikinews(0 entries)

edit

Wikiquote(0 entries)

edit

Wikisource(0 entries)

edit

Wikiversity(0 entries)

edit

Wikivoyage(0 entries)

edit

Wiktionary(0 entries)

edit

Multilingual sites(0 entries)

edit

Retrieved from "https://www.wikidata.org/w/index.php?title=Q56905292&oldid=1526970298"